+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immuno-oncology Clinical Trials Market by Therapy Type (Adoptive Cell Therapies, Cancer Vaccines, Checkpoint Inhibitors), Trial Phase (Phase I, Phase Ii, Phase Iii), Indication, Sponsor Type, Trial Type, Patient Enrollment - Global Forecast 2025-2030- Product Image
Immuno-oncology Clinical Trials Market by Therapy Type (Adoptive Cell Therapies, Cancer Vaccines, Checkpoint Inhibitors), Trial Phase (Phase I, Phase Ii, Phase Iii), Indication, Sponsor Type, Trial Type, Patient Enrollment - Global Forecast 2025-2030- Product Image
Sale

Immuno-oncology Clinical Trials Market by Therapy Type (Adoptive Cell Therapies, Cancer Vaccines, Checkpoint Inhibitors), Trial Phase (Phase I, Phase Ii, Phase Iii), Indication, Sponsor Type, Trial Type, Patient Enrollment - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674772
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Immuno-oncology Clinical Trials Market is experiencing rapid transformation driven by innovation in cancer therapeutic strategies, evolving trial methodologies, and a global push to advance immune-based treatment solutions. Senior decision-makers must understand how shifting scientific, operational, and geopolitical dynamics are redefining clinical development and investment priorities in this highly active segment.

Market Snapshot: Immuno-oncology Clinical Trials Market

The Immuno-oncology Clinical Trials Market grew from USD 6.58 billion in 2024 to USD 7.40 billion in 2025. It is expected to continue growing at a CAGR of 11.84%, reaching USD 12.89 billion by 2030. This accelerated trajectory reflects breakthroughs in checkpoint inhibition, cellular engineering, and the global expansion of trial activity. Growth is further fueled by deeper collaboration between pharmaceutical innovators, biotechnology leaders, and clinical research institutions to target diverse malignancies with emerging immune-based interventions.

Scope & Segmentation

This report delivers a comprehensive analysis of major segments, regional dynamics, and technology trends driving the immuno-oncology clinical trials landscape:

  • Therapy Type: Includes adoptive cell therapies (Car-T, NK cell therapy, TCR-T), cancer vaccines (dendritic cell, DNA, and peptide vaccines), checkpoint inhibitors (CTLA-4, PD-1, PD-L1), cytokine therapies (interferon alpha, interferon gamma, interleukin-2), and oncolytic viruses.
  • Trial Phase: Covers safety, efficacy, and large-scale validation through Phases I, II, III, and IV.
  • Indication: Encompasses hematological malignancies (leukemia, lymphoma, myeloma) and solid tumors (breast, colorectal, lung, melanoma).
  • Sponsor Type: Ranges from academic institutions, biotechnology companies, and pharmaceutical firms to cross-sector consortiums.
  • Trial Type: Classification as interventional or observational.
  • Patient Enrollment: Differentiates by large, medium, and small-scale cohorts, reflecting trial complexity and reach.
  • Geographic Regions: Market insights span the Americas (notably the US, Canada, Brazil, Argentina, Mexico), Europe, Middle East & Africa (including United Kingdom, Germany, France, Saudi Arabia, South Africa), and Asia-Pacific (China, India, Japan, Australia, South Korea, among others).
  • Leading Companies: Analysis includes Bristol-Myers Squibb, Merck & Co., Roche, AstraZeneca, Novartis, Pfizer, Johnson & Johnson, Amgen, Sanofi, and GlaxoSmithKline.

Key Takeaways for Decision-Makers

  • Immuno-oncology trial strategies have shifted from broad-spectrum approaches to highly targeted and personalized therapies, increasing development complexity.
  • Collaborations between academic institutions, biotechs, and global pharmaceutical companies are accelerating translational research and driving diverse innovation pipelines.
  • Technological advancements in genomic profiling, bioinformatics, and digital health are optimizing patient stratification and enhancing data-driven trial execution.
  • Emerging therapies such as bispecific antibodies, multi-specific constructs, and refined cell engineering are enabling new combinations that address resistance mechanisms.
  • Decentralized and adaptive trial designs are supporting broader patient access, improving enrollment rates, and expediting proof-of-concept validation.
  • Regional regulatory harmonization and robust healthcare infrastructure influence trial design, site selection, and global expansion of immuno-oncology programs.

Tariff Impact: Navigating US Tariffs and Supply Chain Adaptation

The introduction of revised United States tariffs in 2025 has heightened operational and financial complexity for immuno-oncology clinical trials. Higher duties on laboratory reagents, specialized equipment, and critical inputs have elevated procurement costs and exposed sponsors to supply chain disruptions and longer lead times. In response, stakeholders are exploring alliances with domestic suppliers, onshoring workflows, and optimizing logistics to maintain trial momentum and minimize risk. Organizations proactively adapting their supply chain strategies are better positioned to sustain progress and innovation in the face of regulatory volatility.

Methodology & Data Sources

This analysis leverages a multi-dimensional methodology that combines in-depth desk research with targeted interviews. Key data were drawn from peer-reviewed publications, regulatory filings, trial registries, and proprietary industry sources. Qualitative insights were captured via discussions with clinical investigators, regulatory experts, and R&D leaders to validate findings and segment trends. Advanced analytics and cross-validation protocols ensured robust, actionable intelligence.

Why This Report Matters

  • Enables strategic allocation of R&D and investment resources by revealing high-potential segments, therapeutic platforms, and trial geographies.
  • Equips senior leaders to anticipate operational risks and adapt to regulatory or supply chain disruptions, maintaining a competitive edge.
  • Delivers an evidence-backed framework for identifying collaborative opportunities and optimizing trial design, patient recruitment, and real-world data integration.

Conclusion

The Immuno-oncology Clinical Trials Market is rapidly evolving, characterized by scientific innovation, shifting regulations, and global expansion. Informed decision-making and proactive adaptation are essential for stakeholders seeking to drive meaningful progress in next-generation cancer care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of bispecific antibody platforms targeting solid tumor microenvironments with dual checkpoint inhibition
5.2. Adoption of personalized neoantigen vaccine strategies integrated with checkpoint blockade therapies
5.3. Development of combination regimens involving CAR T cell therapy and immune checkpoint inhibitors in hematologic malignancies
5.4. Integration of advanced biomarker-driven patient stratification using multiomics for immunotherapy response prediction
5.5. Emergence of off-the-shelf allogeneic natural killer cell therapies engineered with CAR constructs for rapid tumor targeting
5.6. Investigation of microbiome modulation approaches to enhance efficacy and reduce toxicities of cancer immunotherapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immuno-oncology Clinical Trials Market, by Therapy Type
8.1. Introduction
8.2. Adoptive Cell Therapies
8.2.1. Car-T
8.2.2. Nk Cell Therapy
8.2.3. Tcr-T
8.3. Cancer Vaccines
8.3.1. Dendritic Cell Vaccines
8.3.2. Dna Vaccines
8.3.3. Peptide Vaccines
8.4. Checkpoint Inhibitors
8.4.1. Ctla-4 Inhibitors
8.4.2. Pd-1 Inhibitors
8.4.3. Pd-L1 Inhibitors
8.5. Cytokine Therapies
8.5.1. Interferon Therapies
8.5.1.1. Interferon Alpha
8.5.1.2. Interferon Gamma
8.5.2. Interleukin-2
8.6. Oncolytic Viruses
9. Immuno-oncology Clinical Trials Market, by Trial Phase
9.1. Introduction
9.2. Phase I
9.3. Phase Ii
9.4. Phase Iii
9.5. Phase Iv
10. Immuno-oncology Clinical Trials Market, by Indication
10.1. Introduction
10.2. Hematological Malignancies
10.2.1. Leukemia
10.2.2. Lymphoma
10.2.3. Myeloma
10.3. Solid Tumors
10.3.1. Breast Cancer
10.3.2. Colorectal Cancer
10.3.3. Lung Cancer
10.3.4. Melanoma
11. Immuno-oncology Clinical Trials Market, by Sponsor Type
11.1. Introduction
11.2. Academic Institutions
11.3. Biotechnology Companies
11.4. Consortiums
11.5. Pharmaceutical Companies
12. Immuno-oncology Clinical Trials Market, by Trial Type
12.1. Introduction
12.2. Interventional
12.3. Observational
13. Immuno-oncology Clinical Trials Market, by Patient Enrollment
13.1. Introduction
13.2. Large Scale
13.3. Medium Scale
13.4. Small Scale
14. Americas Immuno-oncology Clinical Trials Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Immuno-oncology Clinical Trials Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Immuno-oncology Clinical Trials Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Bristol-Myers Squibb Company
17.3.2. Merck & Co., Inc.
17.3.3. Roche Holding AG
17.3.4. AstraZeneca PLC
17.3.5. Novartis AG
17.3.6. Pfizer Inc.
17.3.7. Johnson & Johnson
17.3.8. Amgen Inc.
17.3.9. Sanofi S.A.
17.3.10. GlaxoSmithKline plc
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET: RESEARCHAI
FIGURE 28. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET: RESEARCHSTATISTICS
FIGURE 29. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET: RESEARCHCONTACTS
FIGURE 30. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 171. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 172. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 173. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2024 (USD MILLION)
TABLE 174. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2025-2030 (USD MILLION)
TABLE 175. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 176. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 177. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 178. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 179. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 180. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 181. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2024 (USD MILLION)
TABLE 182. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2025-2030 (USD MILLION)
TABLE 183. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 184. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 185. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 188. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 189. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 190. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 191. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2024 (USD MILLION)
TABLE 192. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025-2030 (USD MILLION)
TABLE 193. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2024 (USD MILLION)
TABLE 194. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025-2030 (USD MILLION)
TABLE 195. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2024 (USD MILLION)
TABLE 196. CANADA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2025-2030 (USD MILLION)
TABLE 197. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 198. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 199. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2024 (USD MILLION)
TABLE 200. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2025-2030 (USD MILLION)
TABLE 201. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 202. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 203. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 206. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 207. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2024 (USD MILLION)
TABLE 208. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2025-2030 (USD MILLION)
TABLE 209. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 210. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 211. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 214. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 215. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 216. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 217. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2024 (USD MILLION)
TABLE 218. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025-2030 (USD MILLION)
TABLE 219. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2024 (USD MILLION)
TABLE 220. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025-2030 (USD MILLION)
TABLE 221. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2024 (USD MILLION)
TABLE 222. MEXICO IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINIC

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Immuno-oncology Clinical Trials market report include:
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Roche Holding AG
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.89 Billion
Compound Annual Growth Rate11.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Immuno-Oncology Market by Therapy Type (Cancer Vaccines, Cell Therapy, Checkpoint Inhibitors), Indication (Breast Cancer, Colorectal Cancer, Lung Cancer), End User, Line Of Therapy, Mechanism - Global Forecast 2025-2030 - Product Image

Immuno-Oncology Market by Therapy Type (Cancer Vaccines, Cell Therapy, Checkpoint Inhibitors), Indication (Breast Cancer, Colorectal Cancer, Lung Cancer), End User, Line Of Therapy, Mechanism - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Immuno Oncology Assays Market by Technology Type (Flow Cytometry, Immunoassay, Mass Cytometry), Product (Consumables, Instruments), Sample Type, End User, Indication, Application - Global Forecast 2025-2030 - Product Image

Immuno Oncology Assays Market by Technology Type (Flow Cytometry, Immunoassay, Mass Cytometry), Product (Consumables, Instruments), Sample Type, End User, Indication, Application - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From
Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Immuno-Oncology Drugs Market Report 2025 - Product Image

Immuno-Oncology Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Immuno Oncology Clinical Trials Market

Immuno Oncology (IO) is a rapidly growing field of oncology drug development that focuses on harnessing the body's own immune system to fight cancer. IO drugs are designed to target and block specific pathways that cancer cells use to evade the immune system. These drugs can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. IO clinical trials are designed to evaluate the safety and efficacy of these drugs in treating various types of cancer. IO clinical trials are conducted in phases, with each phase designed to assess different aspects of the drug's safety and efficacy. Phase I trials are typically conducted in small groups of patients to assess the drug's safety and tolerability. Phase II trials are larger and are designed to assess the drug's efficacy in treating a specific type of cancer. Phase III trials are the largest and are designed to compare the drug's efficacy to existing treatments. Some of the major companies in the IO clinical trials market include Merck, Bristol-Myers Squibb, AstraZeneca, Roche, and Novartis. These companies are actively involved in the development and testing of IO drugs for the treatment of various types of cancer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.